Managers / Q4 2023 · view latest →
SYQUANT CAPITAL SAS
CIK 0001766392 · 25 AVENUE KLEBER, PARIS, I0, 75116 · 0033142569307
Summary
Syquant Capital Sas reported $22M in U.S.-listed holdings across 7 positions for Q4 2023.
The portfolio is heavily concentrated: Mirati Therapeutics alone accounts for 40.8% of reported value.
Compared with Q3 2023, the fund opened 7 new positions and exited 9.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 57.7% · $13M
- Common Stock · 42.3% · $9M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MIRATI THERAPEUTICS INC | NEW | +153.9K | 153.9K | +$9M | $9M |
| LAZARD LTD | NEW | +206.8K | 206.8K | +$7M | $7M |
| ICOSAVAX INC | NEW | +190.7K | 190.7K | +$3M | $3M |
| KARUNA THERAPEUTICS INC | NEW | +8.1K | 8.1K | +$3M | $3M |
| LOGILOGITECH INTL S A | NEW | +1.4K | 1.4K | +$129,000 | $129,000 |
| FROFRONTLINE PLC | NEW | +6.4K | 6.4K | +$128,000 | $128,000 |
| RACEFERRARI N V | NEW | +243 | 243 | +$82,000 | $82,000 |
| HORIZON THERAPEUTICS PUB L | SOLD OUT | −1.40M | 0 | −$162M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MIRATI THERAPEUTICS INC | COM | 40.81% | $9M | 153.9K |
| 2 | LAZARD LTD | SHS A | 32.48% | $7M | 206.8K |
| 3 | ICOSAVAX INC | COM | 13.56% | $3M | 190.7K |
| 4 | KARUNA THERAPEUTICS INC | COM | 11.61% | $3M | 8.1K |
| 5 | LOGILOGITECH INTL S A | SHS | 0.58% | $129,000 | 1.4K |
| 6 | FROFRONTLINE PLC | COM | 0.58% | $128,000 | 6.4K |
| 7 | RACEFERRARI N V | COM | 0.37% | $82,000 | 243 |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2026 | $447M | 38 | Jul 9, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q1 2026 | $640M | 40 | Apr 10, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $817M | 37 | Jan 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $348M | 17 | Oct 28, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $302M | 14 | Jul 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2025 | $141M | 14 | Apr 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $70M | 6 | Jan 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $27M | 5 | Oct 4, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $10M | 5 | Jul 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $64M | 6 | Apr 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $22M | 7 | Jan 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $255M | 9 | Oct 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $138M | 11 | Jul 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $43M | 7 | Apr 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $41M | 14 | Jan 17, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $165M | 25 | Oct 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $90M | 32 | Jul 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $195M | 35 | Apr 7, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $262M | 43 | Jan 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $164M | 42 | Oct 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $83M | 41 | Jul 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $386M | 53 | Apr 20, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $387M | 81 | Feb 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $196M | 62 | Oct 21, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $215M | 23 | Aug 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $407M | 18 | Apr 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $194M | 16 | Jan 8, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $365M | 17 | Oct 17, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $312M | 14 | Jul 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $258M | 15 | Apr 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $117M | 11 | Feb 4, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.